Mental health care for all, no prescription necessary

Our digital therapeutics are safe and effective non-drug alternatives for mental health.*

Image of a woman confidently looking off into the distance, away from the camera
webp png replacement

Most people in need of mental health care don’t receive it

For those who are able to get care, 82% are given medication – but medication isn’t always the best option.1

58%

of people experience moderately severe side effects.2

<50%

remission rate for the most common medications.3,4

75%

of people prefer a non-drug alternative.5

Our digital therapeutics deliver effective help with no serious side effects

Daylight and Sleepio are easily accessible, safe, and highly effective.6,7

Trusted by the world’s leading organizations

For nearly a decade, we’ve been empowering employers and health plans
to help millions back to good mental health.

Simple to adopt,
low-lift engagement

The easiest way to offer non-drug alternatives to members of your population in need.

An abstract image depicting the Big Health logo being "selected" inside of a checked box.

Add coverage to your
pharmacy plan

Pre-approved by major pharmacy benefit managers, add coverage in as few as 10 days.

An abstract illustration of providing Big Health's digital therapeutics in the health care patient journey.

Offer access via
existing care pathways

Easily reach individuals at the time of need.

An abstract illustration depicting a Big Health invoice alongside other health care invoices. Billing is available via your company's Pharmacy Benefit Manager.

Bill via pharmacy invoice

Deep integrations mean you get to bill for therapeutic use via your pharmacy invoice.

We believe evidence
is a duty, not a chore

We’re committed to gold-standard clinical evidence. Our therapeutics have been validated in more than 32 peer-reviewed clinical evidence studies with more than 13,000 participants, including 13 randomized controlled trials (RCTs).

Daylight logo

71%

of participants moved from clinical to non-clinical worry and anxiety levels.6

Sleepio logo

76%

of participants moved from unhealthy to healthy sleep efficiency.7

*Disclaimer: In accordance with FDA’s Current Enforcement Discretion Policy for Digital Health Devices for Psychiatric Disorders, for patients aged 18 years and older, who are followed by and diagnosed with Insomnia Disorder or Generalized Anxiety Disorder by a medical provider, Sleepio and Daylight can be made available as an adjunct to their usual medical care for Insomnia Disorder or Generalized Anxiety Disorder, respectively. Sleepio and Daylight do not replace the care of a medical provider or the patient’s medication. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for these indications. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.

1. Terlizzi, E. P., & Zablotsky, B. (2020). Mental Health Treatment Among Adults: United States, 2019. NCHS Data Brief, (380), 1-8. 
2. Lembke, A., Papac, J., & Humphreys, K. (2018). Our other prescription drug problem. The New England journal of medicine, 378(8), 693-695.
3. Pillai, V., Roth, T., Roehrs, T., Moss, K., Peterson, E. L., & Drake, C. L. (2017). Effectiveness of benzodiazepine receptor agonists in the treatment of insomnia: an examination of response and remission rates. Sleep, 40(2), zsw044.
4. Rickels, K., & Rynn, M. (2002). Pharmacotherapy of generalized anxiety disorder. The Journal of clinical psychiatry, 63(suppl 14), 9-16.
5. McHugh, R. K., Whitton, S. W., Peckham, A. D., Welge, J. A., & Otto, M. W. (2013). Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. The Journal of clinical psychiatry, 74(6), 0-0.
6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and anxiety, 37(12), 1168-1178.
7. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.